Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $2,247,064.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Trading Down 5.2 %

Shares of NASDAQ:RXST opened at $48.89 on Wednesday. RxSight, Inc. has a 12 month low of $20.66 and a 12 month high of $66.54. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -38.80 and a beta of 1.22. The firm’s 50-day moving average is $51.02 and its 200 day moving average is $53.90.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The firm had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. The company’s quarterly revenue was up 67.6% on a year-over-year basis. As a group, equities analysts forecast that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Institutional Trading of RxSight

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in shares of RxSight in the first quarter worth about $1,929,000. Capstone Investment Advisors LLC purchased a new position in shares of RxSight during the fourth quarter worth approximately $642,000. Principal Financial Group Inc. increased its position in shares of RxSight by 298.5% during the first quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock worth $1,802,000 after acquiring an additional 26,164 shares during the period. Baillie Gifford & Co. bought a new stake in shares of RxSight during the first quarter valued at approximately $3,429,000. Finally, M&G Plc purchased a new stake in shares of RxSight in the first quarter valued at approximately $7,354,000. Hedge funds and other institutional investors own 78.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on RXST. Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a research note on Friday, September 13th. BTIG Research increased their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Oppenheimer decreased their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Stifel Nicolaus dropped their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Wells Fargo & Company decreased their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.